antidiabetic drugs

Albiglutide - Alogliptin - Canagliflozin - Dapagliflozin - Empagliflozin - Exenatide - Glipizide - Glyburide - Liraglutide - Lixisenatide - Metformin - Nateglinide - Nouveau - Pioglitazone - Rosiglitazone - Saxagliptin - Sitagliptin - Sulfonylurea - Taspoglutide - Troglitazone - Voglibose      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

diabetes type 2

albiglutide
Rosenstock (30 mg weekly), 2009albiglutide weeklyplacebo (add on MET)NCT00518115Exploratory suggesting
alogliptin
Nauck, 2009alogliptinplacebo (add on MET)NCT00286442Exploratory negative
dapagliflozin
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET)NCT00528879Exploratory -
glimeripide
Study 201 (Goldberg), 1996glimepirideplaceboExploratory -
Schade, 1998glimepirideplacebo -
Rosenstock, 1996glimepirideplacebo -
Luis Bautista, 2003glimepirideplacebo -
Kaneko, 1993glimepirideplacebo -
Study 202glimepirideplacebo -
Riddle, 1994glimepirideplacebo (add on insulin) -
Charpentier, 2001glimepirideplacebo (add on MET)negative
Draeger, 1996glimepirideglibenclamideLow risk of bias -
Protocol 311glimepirideglibenclamide -
Charpentier (301F)glimepiridegliclazide -
Inukai, 2005glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997glimepiride odglimepiride bid -
Clark (301), 1997glimepirideglipizide -
Dills, 1996glimepirideglyburideExploratory -
glipizide
Goldsteinglipizidecontrol (add on MET) -
Rosenstock, 1993glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Simonson, 1997glipizideplacebo -
Testa, 1998glipizideplacebo -
glyburide
Hermann, 1991glibenclamidec (add on MET) -
DeFronzo, 1995glyburidec (add on MET) -
Erle, 1999glyburidec (add on MET) -
Marre (ass), 2002glibenclamidecontrol (add on MET) -
Tosi, 2003glibenclamidecontrol (add on MET) -
Blonde, 2002glyburidecontrol (add on MET) -
Garber, 2003glyburidecontrol (add on MET) -
Garber, 2002glyburideplacebo -
Vray, 1995glyburideplacebo -
linagliptin
Gallwitz, 2012linagliptinglimepiride (add on MET)NCT00622284 -
linagliptin 1218.62 ongoing linagliptin low doselinagliptinNCT01012037 ongoing
OwenslinagliptinMetformin + sulfonylureaNCT00602472 -
Del PratolinagliptinplaceboNCT00621140 -
linagliptin 1218.65 ongoing linagliptinplacebo (add on MET)NCT01215097 ongoing
linagliptin 1218.61 ongoing linagliptinplacebo (add on MET+TZD)NCT00996658 ongoing
Lewin, 2010linagliptinplacebo (add on SU)NCT00819091 -
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazoneNCT01183013 ongoing
liraglutide
NN2211-1799 ongoing liraglutide other dosesplaceboNCT00620282 ongoing
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)NCT00318461suggesting
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)NCT00318422suggesting
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU)NCT00395746 ongoing
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)NCT00331851suggesting
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)NCT00333151suggesting
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)NCT00333151suggesting
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET)NCT01296412 ongoing
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SUNCT00518882Risk of bias suggesting
Seino, 2010liraglutide other dosesglibenclamideNCT00393718Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NCT00318461negative
EAGLE ongoing liraglutide other dosesinsulin glargineNCT01117350 ongoing
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET)NCT00331851Risk of bias negative
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU)NCT00318422Low risk of bias suggesting
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptinNCT00700817Risk of bias suggesting
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptinNCT00700817Low risk of bias suggesting
lixisenatide
GETGOAL-Llixisenatideplacebo (add on basal insulin)NCT00715624 -
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin)NCT00975286 ongoing
GETGOAL-L-ASIA ongoing lixisenatideplacebo (add on basal insulin)NCT00866658 ongoing
Ratner DRI6012, 2010lixisenatideplacebo (add on MET)NCT00299871Exploratory -
GETGOAL-M ongoing lixisenatideplacebo (add on MET)NCT00712673 ongoing
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU)NCT01169779 ongoing
GETGOAL-S ongoing lixisenatideplacebo (add on SU+/-MET)NCT00713830 ongoing
GETGOAL-P ongoing lixisenatideplacebo (add on TZD+/-MET)NCT00763815 ongoing
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET)NCT00976937 ongoing
mitiglinide
GaomitiglinidenateglinideNCT00461617 -
Kumashiro, 2007mitiglinideon top insulin glargine -
Kaku, 2009mitiglinideplacebo (on top pioglitazone) -
nateglinide
Marre, 2002nateglinideplaceboExploratory -
Horton, 2000nateglinideplacebo -
Hanefeld, 1990nateglinideplacebo -
Saloranta, 2002nateglinideplacebo -
Mari, 2005nateglinideplacebo -
Moses, 2001nateglinideplacebo -
Goldberg, 1998repaglinideplacebo -
Jovanovic, 2000repaglinideplacebo -
Bech, 2003repaglinideplacebo -
Li, 2009nategliniderepaglinide -
Li, 2007nategliniderepaglinide -
Ristic, 2006nateglinidegliclazide (add on MET)Exploratory -
nouveau
Buse, 2011exenatide 20µg/dplacebo (add on insulin)NCT00765817Low risk of bias negative
Fineman, 2003exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005exenatide 10µg/dplacebo (add on MET)NCT00039013Low risk of bias negative
DeFronzo 20µg/d, 2005exenatide 20µg/dplacebo (add on MET)NCT00039013suggesting
Kim, 2007exenatide weeklyplacebo (add on MET)NCT00103935Exploratory negative
Gao, 2009exenatide 20µg/dplacebo (add on MET+/-SU)NCT00324363Low risk of bias suggesting
Buse 10µg/d, 2004exenatide 10µg/dplacebo (add on SU)NCT00039026negative
Buse 20µg/d, 2004exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005exenatide 10µg/dplacebo (add on SU+MET)NCT00035984Low risk of bias negative
Kendall 20µg/d, 2005exenatide 20µg/dplacebo (add on SU+MET)NCT00035984Low risk of bias suggesting
Zinman 20µg/j, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)NCT00099320suggesting
Zinman 20µg/j A MODIFIER, 2007exenatide 20µg/dplacebo (add on TZD+/-MET) -
phase 2 exenatide once monthlyexenatide once monthlyweekly exenatide -
Exenatide Trial 10749exenatide before lunch and dinnerexenatide before breakfast and dinnerRisk of bias -
Heine, 2005exenatide 20µg/dinsulin (add on SU+MET)negative
Davis, 2007exenatide 20µg/dinsulin (add on SU/MET)NCT00099333Risk of bias negative
Barnett, 2007exenatide 20µg/dinsulin (add on SU/MET)NCT00099619Exploratory suggesting
Nauck, 2007exenatide 20µg/dinsulin BIAsp twice daily add on SU+METNCT00082407Risk of bias negative
DURATION-3 (Diamant), 2010exenatide weeklyinsulin glargineNCT00641056Risk of bias suggesting
Trial 8078exenatide other dosesinsulin glargine (add on MET/SU) -
pioglitazone
PNFP-014pioglitazone + insulinplacebo (add on insulin)Exploratory negative
OPI-502pioglitazone + insulinplacebo (add on insulin)Exploratory negative
repaglinide
Moses, 1999repaglinidecontrol (add on MET)Exploratory -
Landgraf, 1999repaglinideglibenclamide -
Marbury, 1999repaglinideglibenclamide -
Wolffenbuttel, 1999repaglinideglibenclamide -
Madsbad, 2001repaglinideglipizide -
Lund, 2007repaglinidemetformin -
Raskin, 2001repaglinideon top pioglitazone -
Raskin, 2001repaglinideon top rosiglitazone -
Raskin, 2000repaglinideon top troglitazone -
Chuang, 1999repaglinideplacebo -
Goldberg, 1998repaglinideplaceboExploratory -
Jovanovic, 2000repaglinideplacebo -
Landin-Olsson, 1999repaglinideplacebo (on top bedtime NPH-insulin) -
rosiglitazone
SB-712753/009 rosiglitazoneExploratory -
49653/136 rosiglitazoneplaceboExploratory -
BRL 49653/347 rosiglitazoneplacebo (add on insulin)NCT00054782Exploratory -
49653/085 rosiglitazoneplacebo (add on insulin)Exploratory -
49653/095 rosiglitazoneplacebo (add on insulin)Exploratory -
saxagliptin
saxgliptin, renal studysaxagliptinplacebo (add on current treatment) -
CV181-057saxagliptinplacebo (add on insulin)NCT00757588 -
DeFronzo, 2009saxagliptinplacebo (add on MET)NCT00121667negative
CV181-080saxagliptinplacebo (add on MET)NCT00885378 -
Jadzinsky, 2009saxagliptinplacebo (add on MET)NCT00327015 -
CV181-066saxagliptinplacebo (add on MET)NCT00683657 -
Hollandersaxagliptinplacebo (add on TZD)NCT00295633 -
Rosenstock, 2008saxagliptinplacebo (monotherapy)NCT00950599 -
CV181-011saxagliptinplacebo (monotherapy)NCT00121641 -
CV181-038saxagliptinplacebo (monotherapy)NCT00316082 -
CV181-041saxagliptinplacebo (monotherapy)NCT00374907 -
saxagliptin vs sitagliptinsaxagliptinsitagliptin (add on MET) -
sitagliptin
Charbonnel, 2006sitagliptinplacebo (add on MET)NCT0086515negative
Nauck, 2007sitagliptinplacebo (add on MET)NCT00094770negative
Scott** (sit vs pbo on top met), 2007sitagliptinplacebo (add on MET)negative
Rosenstock (sit on top pio vs pbo), 2006sitagliptinplacebo (on top PIO)NCT00086502suggesting
Hermansen, 2007sitagliptinplacebo (on-top glimepiride+/- metformine)negative
taspoglutide
BC21713 (vs placebo) ongoing taspoglutideplaceboNCT00754988 ongoing
BC20963 ongoing taspoglutideplaceboNCT00744367 ongoing
Nauck 10 once weekly vs PBO, 2009taspoglutide 10mg once weeklyplaceboNCT00423501Exploratory suggesting
Ratner (20mg once weekly), 2010taspoglutideplacebo (add on MET)NCT00460941Exploratory suggesting
BC22092 ongoing taspoglutideplacebo (add on MET)NCT00823992 ongoing
BC21625 ongoing taspoglutideexenatideNCT00717457 ongoing
ZC22565 ongoing taspoglutideinsulin glargineNCT01051011 ongoing
BC20965 ongoing taspoglutideinsulin glargine (add on MET)NCT00755287 ongoing
BC21893 ongoing taspoglutidepioglitazoneNCT00909597 ongoing
vildagliptin
Fonseca, 2007vildagliptinplacebo (add on insulin)NCT00099931suggesting
Ahren, 2004vildagliptinplacebo (add on MET)negative
Bosi, 2007vildagliptinplacebo (add on MET)NCT00099892negative
Goodman, 2009vildagliptinplacebo (add on MET)Exploratory negative
Garber, 2007vildagliptinplacebo (on top pioglitazone)NCT00099853negative
Ferrannini, 2009vildagliptinSulfonylurea (add on to MET)NCT00106340Exploratory suggesting
Bolli, 2008vildagliptinpioglitazone (add on MET)NCT00237237negative
Rosenstock** (vilda + pio vs pio), 2007vildagliptinplacebo (add on TZD)NCT00101803negative